Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Core Insights - Myriad Genetics has completed the acquisition of select assets from Intermountain Health's Intermountain Precision Genomics laboratory business, which includes the Precise™ Tumor Test and the Precise Liquid Test [1][2] - The Precise Tumor Test analyzes tumor DNA to identify important variants and match patients with advanced solid tumors to appropriate therapies and clinical trials [1] - The upcoming Precise Liquid Test will provide genomic profiling results from a blood draw and has completed validation studies for Medicare reimbursement [2] Company Overview - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health and well-being through genetic tests that assess disease risk and guide treatment decisions [3]